Fig. 8
HIF-1α inhibitor abolishes the tumor-promoting effects of PDLIM2 downregulation. A C57BL/6 mice (n = 6) were injected subcutaneously with 5 × 105 control and PDLIM2 knockdown LLC cells. When the tumors reached approximately 300 mm3, the mice were orally administered PX-478 three times per week for 2 weeks. B Tumor volume was measured at the indicated times, and the mean tumor size was plotted. Mice were euthanized on day 22, and tumors were excised and photographed (right panel). C The body weight of each mouse was measured. D Total RNAs from the tumors were isolated using TRIzol reagent, and the mRNA expression levels of HIF-1α and PDLIM2 were measured by real-time PCR. The expression levels were normalized to β-actin mRNA levels. E Protein levels of HIF-1α were measured by immunoblotting in tumor tissues. F Immunohistochemistry of tumor samples for HIF-1α positive tumor cells (left upper panel: 20X, left lower panel: 40X). HIF-1α-positive area scores were evaluated by using ImageJ software at 20X magnification filed (Right panel). Data represent means ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001 compared with the shEmpty group